These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30258789)

  • 1. The use of structural alerts to avoid the toxicity of pharmaceuticals.
    Limban C; Nuţă DC; Chiriţă C; Negreș S; Arsene AL; Goumenou M; Karakitsios SP; Tsatsakis AM; Sarigiannis DA
    Toxicol Rep; 2018; 5():943-953. PubMed ID: 30258789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes.
    Dang NL; Hughes TB; Miller GP; Swamidass SJ
    Chem Res Toxicol; 2017 Apr; 30(4):1046-1059. PubMed ID: 28256829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries.
    Liu R; Yu X; Wallqvist A
    J Cheminform; 2015; 7():4. PubMed ID: 25717346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
    Kalgutkar AS; Didiuk MT
    Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs.
    Kalgutkar AS
    Curr Med Chem; 2015; 22(4):438-64. PubMed ID: 25388012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species.
    Argikar UA; Mangold JB; Harriman SP
    Curr Top Med Chem; 2011; 11(4):419-49. PubMed ID: 21320068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioalerts: a python library for the derivation of structural alerts from bioactivity and toxicity data sets.
    Cortes-Ciriano I
    J Cheminform; 2016; 8():13. PubMed ID: 26949417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ToxAlerts: a Web server of structural alerts for toxic chemicals and compounds with potential adverse reactions.
    Sushko I; Salmina E; Potemkin VA; Poda G; Tetko IV
    J Chem Inf Model; 2012 Aug; 52(8):2310-6. PubMed ID: 22876798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
    Orhan H; Vermeulen NP
    Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing around Structural Alerts in Drug Discovery.
    Kalgutkar AS
    J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists.
    Edwards PJ; Sturino C
    Curr Med Chem; 2011; 18(20):3116-35. PubMed ID: 21651480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the in vitro bioactivation of aminopyrazole derivatives: trapping reactive aminopyrazole intermediates using glutathione ethyl ester in human liver microsomes.
    Ryan E; Morrow BJ; Hemley CF; Pinson JA; Charman SA; Chiu FC; Foitzik RC
    Chem Res Toxicol; 2015 Sep; 28(9):1747-52. PubMed ID: 26317231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactivation of drugs: risk and drug design.
    Walsh JS; Miwa GT
    Annu Rev Pharmacol Toxicol; 2011; 51():145-67. PubMed ID: 21210745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?
    Kalgutkar AS; Fate G; Didiuk MT; Bauman J
    Expert Rev Clin Pharmacol; 2008 Jul; 1(4):515-31. PubMed ID: 24410554
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.